Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'Atypical antipsychotics'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study / Benjamin A. ADLER in Autism, 19-1 (January 2015)
[article]
Titre : Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study Type de document : Texte imprimé et/ou numérique Auteurs : Benjamin A. ADLER, Auteur ; Logan K. WINK, Auteur ; Maureen EARLY, Auteur ; Rebecca SHAFFER, Auteur ; Noha MINSHAWI, Auteur ; Christopher J. MCDOUGLE, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.102-106 Langues : Anglais (eng) Mots-clés : aggression atypical antipsychotics autism autism spectrum disorders self-injurious behavior severe tantrums Index. décimale : PER Périodiques Résumé : Aggression, self-injurious behavior, and severe tantrums are impairing symptoms frequently experienced by individuals with autism spectrum disorders. Despite US Food and Drug Administration approval of two atypical antipsychotics targeting these symptoms in youth with autistic disorder, they remain frequently drug refractory. We define drug-refractory aggression, self-injurious behavior, and severe tantrums in people with autism spectrum disorders as behavioral symptoms requiring medication adjustment despite previous trials of risperidone and aripiprazole or previous trials of three psychotropic drugs targeting the symptom cluster, one of which was risperidone or aripiprazole. We reviewed the medical records of individuals of all ages referred to our clinic for autism spectrum disorder diagnostic evaluation, as well as pharmacotherapy follow-up notes for all people meeting autism spectrum disorder criteria, for drug-refractory symptoms. Among 250 consecutively referred individuals, 135 met autism spectrum disorder and enrollment criteria, and 53 of these individuals met drug-refractory symptom criteria. Factors associated with drug-refractory symptoms included age 12 years or older (p < 0.0001), diagnosis of autistic disorder (p = 0.0139), and presence of intellectual disability (p = 0.0273). This pilot report underscores the significance of drug-refractory aggression, self-injurious behavior, and severe tantrums; suggests the need for future study clarifying factors related to symptom development; and identifies the need for focused treatment study of this impairing symptom domain. En ligne : http://dx.doi.org/10.1177/1362361314524641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=245
in Autism > 19-1 (January 2015) . - p.102-106[article] Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study [Texte imprimé et/ou numérique] / Benjamin A. ADLER, Auteur ; Logan K. WINK, Auteur ; Maureen EARLY, Auteur ; Rebecca SHAFFER, Auteur ; Noha MINSHAWI, Auteur ; Christopher J. MCDOUGLE, Auteur ; Craig ERICKSON, Auteur . - p.102-106.
Langues : Anglais (eng)
in Autism > 19-1 (January 2015) . - p.102-106
Mots-clés : aggression atypical antipsychotics autism autism spectrum disorders self-injurious behavior severe tantrums Index. décimale : PER Périodiques Résumé : Aggression, self-injurious behavior, and severe tantrums are impairing symptoms frequently experienced by individuals with autism spectrum disorders. Despite US Food and Drug Administration approval of two atypical antipsychotics targeting these symptoms in youth with autistic disorder, they remain frequently drug refractory. We define drug-refractory aggression, self-injurious behavior, and severe tantrums in people with autism spectrum disorders as behavioral symptoms requiring medication adjustment despite previous trials of risperidone and aripiprazole or previous trials of three psychotropic drugs targeting the symptom cluster, one of which was risperidone or aripiprazole. We reviewed the medical records of individuals of all ages referred to our clinic for autism spectrum disorder diagnostic evaluation, as well as pharmacotherapy follow-up notes for all people meeting autism spectrum disorder criteria, for drug-refractory symptoms. Among 250 consecutively referred individuals, 135 met autism spectrum disorder and enrollment criteria, and 53 of these individuals met drug-refractory symptom criteria. Factors associated with drug-refractory symptoms included age 12 years or older (p < 0.0001), diagnosis of autistic disorder (p = 0.0139), and presence of intellectual disability (p = 0.0273). This pilot report underscores the significance of drug-refractory aggression, self-injurious behavior, and severe tantrums; suggests the need for future study clarifying factors related to symptom development; and identifies the need for focused treatment study of this impairing symptom domain. En ligne : http://dx.doi.org/10.1177/1362361314524641 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=245 Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review / Seema JAIN in Journal of Autism and Developmental Disorders, 46-4 (April 2016)
[article]
Titre : Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review Type de document : Texte imprimé et/ou numérique Auteurs : Seema JAIN, Auteur ; Rebecca R. ANDRIDGE, Auteur ; Jessica A. HELLINGS, Auteur Article en page(s) : p.1344-1353 Langues : Anglais (eng) Mots-clés : Loxapine Metabolic side effects Autism spectrum disorder Atypical antipsychotics Index. décimale : PER Périodiques Résumé : Loxapine substitution is a promising option for patients with autism spectrum disorder (ASD) who develop antipsychotic-induced metabolic illness. We performed a chart review of 15 adolescents and adults meeting DSM-IV-TR criteria for ASD, all with antipsychotic-associated weight gain, who received low dose loxapine in an attempt to taper or discontinue the weight gain-associated antipsychotic. Mean weight loss was ?5.7 kg, mean BMI reduction was ?1.9, and mean triglyceride reduction was ?33.7 mg/dl. At chart review, 14 of 15 subjects were rated 2 (Much Improved) or 1 (Very Much Improved) on the Clinical Global Impressions-Improvement scale (CGI-I). Low dose loxapine addition in most cases enabled taper of offending antipsychotics, significantly reversed drug-induced metabolic disturbances and improved irritability. En ligne : http://dx.doi.org/10.1007/s10803-015-2675-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1344-1353[article] Loxapine for Reversal of Antipsychotic-Induced Metabolic Disturbances: A Chart Review [Texte imprimé et/ou numérique] / Seema JAIN, Auteur ; Rebecca R. ANDRIDGE, Auteur ; Jessica A. HELLINGS, Auteur . - p.1344-1353.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1344-1353
Mots-clés : Loxapine Metabolic side effects Autism spectrum disorder Atypical antipsychotics Index. décimale : PER Périodiques Résumé : Loxapine substitution is a promising option for patients with autism spectrum disorder (ASD) who develop antipsychotic-induced metabolic illness. We performed a chart review of 15 adolescents and adults meeting DSM-IV-TR criteria for ASD, all with antipsychotic-associated weight gain, who received low dose loxapine in an attempt to taper or discontinue the weight gain-associated antipsychotic. Mean weight loss was ?5.7 kg, mean BMI reduction was ?1.9, and mean triglyceride reduction was ?33.7 mg/dl. At chart review, 14 of 15 subjects were rated 2 (Much Improved) or 1 (Very Much Improved) on the Clinical Global Impressions-Improvement scale (CGI-I). Low dose loxapine addition in most cases enabled taper of offending antipsychotics, significantly reversed drug-induced metabolic disturbances and improved irritability. En ligne : http://dx.doi.org/10.1007/s10803-015-2675-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284